2/253/1684670437 |
您所在的位置：网站首页 › 2/253/1684670437 |
data-id="" iid="">PubMedhttps://pubmed.ncbi.nlm.nih.gov/28851764FTBMT, a Novel and Selective GPR52 Agonist, Demonstrates ... - PubMed网页In the current study, we investigated the in vitro and in vivo pharmacologic activities of a novel GPR52 agonist, 4-(3-(3-fluoro-5-(trifluoromethyl)benzyl)-5-methyl-1H-1,2,4-triazol-1-yl)-2-methylbenzamide (FTBMT). FTBMT functioned as a selective GPR52 agonist in vitro and in vivo, as demonstrated by the activation of Camp signaling in striatal ...
发布时间：2024-07-06data-id="" iid="">PubMedhttps://pubmed.ncbi.nlm.nih.gov/35347549Invasive lobular carcinoma: an understudied emergent …网页Invasive lobular carcinoma (ILC) is the second most common histologic subtype of breast cancer after invasive ductal carcinoma (IDC), accounting for 10-15% of all breast cancer cases. Although most ILCs are of the luminal A intrinsic subtype, with favorable prognostic features, conflicting literature data are available on their outcomes ...
发布时间：2024-07-06data-id="" iid="">PubMedhttps://pubmed.ncbi.nlm.nih.gov/31945157Outcomes of patients with limited-stage aggressive large B …网页2020年1月28日 · UL1 TR001863/TR/NCATS NIH HHS/United States. There is a paucity of data regarding outcomes and response to standard therapy in patients with limited-stage (LS) agressive B-cell lymphoma (LS-ABCL) who harbor MYC rearrangement (MYC-R) with or without BCL2 and/or BCL6 rearrangements. We conducted a multicenter retrospective …
发布时间：2024-07-06data-id="" iid="">PubMedhttps://pubmed.ncbi.nlm.nih.gov/34877694DBS of Thalamic Centromedian Nucleus for Lennox-Gastaut ... - PubMed网页Abstract. Objective: Prior uncontrolled studies have reported seizure reductions following deep brain stimulation (DBS) in patients with Lennox-Gastaut syndrome (LGS), but evidence from randomized controlled studies is lacking. We aimed to formally assess the efficacy and safety of DBS to the centromedian thalamic nucleus (CM) for the treatment ...
发布时间：2024-07-06